{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:28:53Z","timestamp":1793737733264,"version":"4.6.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) evaluated the efficacy and safety of a novel ruxolitinib dosing strategy with a reduced starting dose with delayed up-titration in anemic MF patients. Fifty-one patients with primary MF (66.7%), post-essential thrombocythemia MF (21.6%), or post-polycythemia vera MF (11.8%) with palpable splenomegaly and hemoglobin &lt;10\u2009g\/dl were included. Median age was 67 (45\u201388) years, 41.2% were female, and 18% were transfusion-dependent. Patients received 10\u2009mg ruxolitinib b.i.d. for the first 12 weeks, then up-titrations of up to 25\u2009mg b.i.d. were permitted, based on efficacy and platelet counts. Overall, 70% of patients achieved a \u226550% reduction in palpable spleen length at any time during the study. The most frequent adverse events leading to dose interruption\/adjustment were thrombocytopenia (17.6%) and anemia (11.8%). Patients who had a dose increase had greater spleen size and higher white blood cell counts at baseline. Median hemoglobin levels remained stable and transfusion requirements did not increase compared with baseline. These results reinforce the notion that it is unnecessary to delay or withhold ruxolitinib because of co-existent or treatment-emergent anemia.<\/jats:p>","DOI":"10.1038\/s41375-021-01261-x","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T08:02:47Z","timestamp":1621497767000},"page":"3455-3465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2664-8131","authenticated-orcid":false,"given":"Francisco","family":"Cervantes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanas","family":"Radinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr","family":"Myasnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Zachee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-5289","authenticated-orcid":false,"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geralyn","family":"Gilotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evren","family":"Zor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-2239","authenticated-orcid":false,"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1261_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273\u201387.","journal-title":"Immunol Rev"},{"key":"1261_CR3","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054\u201361.","journal-title":"Lancet"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779\u201390.","journal-title":"N Engl J Med"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","volume":"60","author":"OI Abdel-Wahab","year":"2009","unstructured":"Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment. Annu Rev Med. 2009;60:233\u201345.","journal-title":"Annu Rev Med"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68\u201376.","journal-title":"Cancer"},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang M-J, Bashey A, Bolwell BJ, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transpl. 2010;16:358\u201367.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1261_CR8","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","volume":"25","author":"D McLornan","year":"2019","unstructured":"McLornan D, Szydlo R, Koster L, Chalandon Y, Robin M, Wolschke C, et al. Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2019;25:2167\u201371.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2018;93:1551\u201360.","journal-title":"Am J Hematol"},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"1261_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0032-9","volume":"7","author":"A Tefferi","year":"2017","unstructured":"Tefferi A. Anemia in myelofibrosis-prevalence, the U2AF1 connection, new treatments. Blood Cancer J. 2017;7:648.","journal-title":"Blood Cancer J"},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1586\/17474086.2016.1154452","volume":"9","author":"F Cervantes","year":"2016","unstructured":"Cervantes F, Correa JG, Hern\u00e1ndez-Boluda JC. Alleviating anemia and thrombocytopenia in myelofibrosis patients. Expert Rev Hematol. 2016;9:489\u201396.","journal-title":"Expert Rev Hematol"},{"key":"1261_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0054-y","volume":"8","author":"T Barbui","year":"2018","unstructured":"Barbui T, Thiele J, Gisslinger H, Kvasnicka HM, Vannucchi AM, Gugliemelli P, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8:15.","journal-title":"Blood Cancer J"},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22:437\u20138.","journal-title":"Leukemia"},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895\u2013901.","journal-title":"Blood"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115:1703\u20138.","journal-title":"Blood"},{"key":"1261_CR17","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29:392\u20137.","journal-title":"J Clin Oncol"},{"key":"1261_CR18","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F. How I treat myelofibrosis. Blood. 2014;124:2635\u201342.","journal-title":"Blood"},{"key":"1261_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/17474086.2013.827413","volume":"6","author":"C Harrison","year":"2013","unstructured":"Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, et al. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol. 2013;6:511\u201323.","journal-title":"Expert Rev Hematol"},{"key":"1261_CR20","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/21678707.2019.1664900","volume":"7","author":"P Bose","year":"2019","unstructured":"Bose P. Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis. Expert Opin Orphan Drugs. 2019;7:415\u201325.","journal-title":"Expert Opin Orphan Drugs"},{"key":"1261_CR21","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","volume":"4","author":"TS Oh","year":"2020","unstructured":"Oh TS, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, et al. ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Adv. 2020;4:4282\u201391.","journal-title":"Blood Adv"},{"key":"1261_CR22","unstructured":"JAKAVI (ruxolitinib) Summary of Product Characteristics. 2019. Novartis Pharm GmbH, Nuremberg, Germany.\u00a0https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jakavi-epar-product-information_en.pdf. Accessed 13 December, 2019."},{"key":"1261_CR23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799\u2013807.","journal-title":"N Engl J Med"},{"key":"1261_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787\u201398.","journal-title":"N Engl J Med"},{"key":"1261_CR25","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3109\/10428194.2016.1146950","volume":"57","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. Leuk Lymphoma. 2016;57:2464\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1261_CR26","unstructured":"ClinicalTrials.gov. NCT02966353. Efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients. (REALISE). Novartis Pharmaceuticals. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02966353?term=NCT02966353&draw=2&rank=1. Accessed 17 Dec 2019."},{"key":"1261_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood"},{"key":"1261_CR28","unstructured":"U.S. Department of Health and Human Services. CTCAE 4.03. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf. Accessed 17 Dec 2019."},{"key":"1261_CR29","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117\u201327.","journal-title":"N Engl J Med."},{"key":"1261_CR30","doi-asserted-by":"publisher","first-page":"79073","DOI":"10.18632\/oncotarget.18674","volume":"8","author":"F Palandri","year":"2017","unstructured":"Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B, et al. Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget. 2017;8:79073\u201386.","journal-title":"Oncotarget"},{"key":"1261_CR31","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica. 2016;101:1065\u201373.","journal-title":"Haematologica"},{"key":"1261_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.16462","volume":"189","author":"HK Al-Ali","year":"2020","unstructured":"Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020;189:888\u2013903.","journal-title":"Br J Haematol"},{"key":"1261_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40164-015-0021-2","volume":"4","author":"MF McMullin","year":"2015","unstructured":"McMullin MF, Harrison CN, Niederwieser D, Demuyinck H, J\u00e4kel N, Gopalakrishna P, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.","journal-title":"Exp Hematol Oncol"},{"key":"1261_CR34","doi-asserted-by":"crossref","unstructured":"Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK,\u00a0et al. Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Leuk Lymphoma. 2021;62:918\u201326.","DOI":"10.1080\/10428194.2020.1845334"},{"key":"1261_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol. 2015;170:29\u201339.","journal-title":"Br J Haematol"}],"updated-by":[{"DOI":"10.1038\/s41375-021-01396-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01261-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:11:13Z","timestamp":1638292273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01261-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01261-x","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41375-021-01396-x","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-021-01396-x","URL":"https:\/\/doi.org\/10.1038\/s41375-021-01396-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FC has served on speakers\u2019 bureaus and advisory boards for Celgene and Novartis. DMR has received consultancy fees, honoraria, and research funding from Novartis, consultancy fees and honoraria from Bristol-Myers Squibb and Celgene, and research funding from Celgene. FPal has received speaker\u2019s honoraria from Novartis. AMV has served on speakers\u2019 bureaus for Gilead and Shire, and has served on the board of directors, speakers\u2019 bureaus or advisory committees for and received research funding from Novartis. HG has received consultancy fees, honoraria, and research funding from, and served on speakers\u2019 bureaus for AOP ORPHAN and Celgene, has received consultancy fees, honoraria, and research funding from Novartis, has received honoraria from and has served on speakers\u2019 bureaus for Janssen Cilag. NK has received research funding from Fuso Pharmaceutical Industries and Wako Pure Chemical Industries, has received research funding from and has served on speakers\u2019 bureaus for PharmaEssentia and Takeda, and has served on speakers\u2019 bureaus for Novartis. LF has received consultancy fees from Pfizer, research funding from Constellation, Gilead, Incyte, and Promedior, and consultancy fees, honoraria, and research funding from Novartis. FPas has served on speakers\u2019 bureaus for Novartis and Celgene\/BMS. GG, IS, RT, and EZ are employees of Novartis. HKA-A has received consultancy fees, honoraria, and research funding from Novartis and Celgene, honoraria from Alexion, and consultancy fees and honoraria from Gilead. AR, AM, PZ, FM declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}